REGNRegeneron PharmaceuticalsRunning, no new patients
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Advanced Non-Small Cell Lung Cancer
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 2/3
- Patients
- 149 (final count)
- Started
- Jun 30, 2023
- Main results expected
- Sep 28, 2027
- Fully finished
- Sep 28, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective response rate (ORR) as assessed by blinded independent central review (BICR), using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
Measured over: Up to 136 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05785767 · record last updated 2026-07-02 · checked 2026-11-09 15:47 UTC